Sign up to save your podcasts
Or
Share Brazil's SaMD Shift: Pure Global on Cracking ANVISA's New Digital Health Code
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Brazil's SaMD Shift: Pure Global on Cracking ANVISA's New Digital Health Code
A major regulatory shift just hit Brazil, Latin America's top MedTech market. Last week, the national agency ANVISA rolled out a completely new framework for Software as a Medical Device (SaMD), creating urgent challenges and new opportunities for digital health companies worldwide. This update introduces a stricter, four-tiered risk classification system and demands more rigorous technical documentation, especially for AI- and machine learning-driven software.
This change means the old way of registering your SaMD product in Brazil is no longer valid. Consider a European startup with an innovative AI diagnostic tool that analyzes patient data to predict disease progression. Under the previous, more ambiguous rules, they were preparing for a mid-tier regulatory process. Now, their product is definitively classified as high-risk, requiring extensive new evidence on clinical validation, data privacy, and cybersecurity that they hadn't budgeted for, potentially delaying their market entry by months.
Key questions from this episode:
- How does ANVISA's new risk classification system impact your AI-powered diagnostic tool?
- What specific cybersecurity and data privacy documents are now mandatory for your submission?
- How has the definition of a medical device been expanded to include your wellness or diagnostic app?
- What are the new, stringent requirements for clinical validation for high-risk SaMD?
- How can you perform a gap analysis between your existing technical file and the new Brazilian requirements?
- Will your existing ISO 13485 certification be enough to meet the new quality management system expectations for software?
- How will these changes affect registration timelines and costs for entering the Brazilian market?
At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you adapt your strategy, update your technical dossiers, and ensure a successful launch in Brazil and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/.
View all episodes
By Ran ChenA major regulatory shift just hit Brazil, Latin America's top MedTech market. Last week, the national agency ANVISA rolled out a completely new framework for Software as a Medical Device (SaMD), creating urgent challenges and new opportunities for digital health companies worldwide. This update introduces a stricter, four-tiered risk classification system and demands more rigorous technical documentation, especially for AI- and machine learning-driven software.
This change means the old way of registering your SaMD product in Brazil is no longer valid. Consider a European startup with an innovative AI diagnostic tool that analyzes patient data to predict disease progression. Under the previous, more ambiguous rules, they were preparing for a mid-tier regulatory process. Now, their product is definitively classified as high-risk, requiring extensive new evidence on clinical validation, data privacy, and cybersecurity that they hadn't budgeted for, potentially delaying their market entry by months.
Key questions from this episode:
- How does ANVISA's new risk classification system impact your AI-powered diagnostic tool?
- What specific cybersecurity and data privacy documents are now mandatory for your submission?
- How has the definition of a medical device been expanded to include your wellness or diagnostic app?
- What are the new, stringent requirements for clinical validation for high-risk SaMD?
- How can you perform a gap analysis between your existing technical file and the new Brazilian requirements?
- Will your existing ISO 13485 certification be enough to meet the new quality management system expectations for software?
- How will these changes affect registration timelines and costs for entering the Brazilian market?
At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you adapt your strategy, update your technical dossiers, and ensure a successful launch in Brazil and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/.